Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories
Standard
Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. / Gerhauser, Clarissa; Favero, Francesco; Risch, Thomas; Simon, Ronald; Feuerbach, Lars; Assenov, Yassen; Heckmann, Doreen; Sidiropoulos, Nikos; Waszak, Sebastian M; Hübschmann, Daniel; Urbanucci, Alfonso; Girma, Etsehiwot G; Kuryshev, Vladimir; Klimczak, Leszek J; Saini, Natalie; Stütz, Adrian M; Weichenhan, Dieter; Böttcher, Lisa-Marie; Toth, Reka; Hendriksen, Josephine D; Koop, Christina; Lutsik, Pavlo; Matzk, Sören; Warnatz, Hans-Jörg; Amstislavskiy, Vyacheslav; Feuerstein, Clarissa; Raeder, Benjamin; Bogatyrova, Olga; Schmitz, Eva-Maria; Hube-Magg, Claudia; Kluth, Martina; Huland, Hartwig; Graefen, Markus; Lawerenz, Chris; Henry, Gervaise H; Yamaguchi, Takafumi N; Malewska, Alicia; Meiners, Jan; Schilling, Daniela; Reisinger, Eva; Eils, Roland; Schlesner, Matthias; Strand, Douglas W; Bristow, Robert G; Boutros, Paul C; von Kalle, Christof; Gordenin, Dmitry; Sültmann, Holger; Brors, Benedikt; Sauter, Guido; Plass, Christoph; Yaspo, Marie-Laure; Korbel, Jan O; Schlomm, Thorsten; Weischenfeldt, Joachim.
in: CANCER CELL, Jahrgang 34, Nr. 6, 10.12.2018, S. 996-1011.e8.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories
AU - Gerhauser, Clarissa
AU - Favero, Francesco
AU - Risch, Thomas
AU - Simon, Ronald
AU - Feuerbach, Lars
AU - Assenov, Yassen
AU - Heckmann, Doreen
AU - Sidiropoulos, Nikos
AU - Waszak, Sebastian M
AU - Hübschmann, Daniel
AU - Urbanucci, Alfonso
AU - Girma, Etsehiwot G
AU - Kuryshev, Vladimir
AU - Klimczak, Leszek J
AU - Saini, Natalie
AU - Stütz, Adrian M
AU - Weichenhan, Dieter
AU - Böttcher, Lisa-Marie
AU - Toth, Reka
AU - Hendriksen, Josephine D
AU - Koop, Christina
AU - Lutsik, Pavlo
AU - Matzk, Sören
AU - Warnatz, Hans-Jörg
AU - Amstislavskiy, Vyacheslav
AU - Feuerstein, Clarissa
AU - Raeder, Benjamin
AU - Bogatyrova, Olga
AU - Schmitz, Eva-Maria
AU - Hube-Magg, Claudia
AU - Kluth, Martina
AU - Huland, Hartwig
AU - Graefen, Markus
AU - Lawerenz, Chris
AU - Henry, Gervaise H
AU - Yamaguchi, Takafumi N
AU - Malewska, Alicia
AU - Meiners, Jan
AU - Schilling, Daniela
AU - Reisinger, Eva
AU - Eils, Roland
AU - Schlesner, Matthias
AU - Strand, Douglas W
AU - Bristow, Robert G
AU - Boutros, Paul C
AU - von Kalle, Christof
AU - Gordenin, Dmitry
AU - Sültmann, Holger
AU - Brors, Benedikt
AU - Sauter, Guido
AU - Plass, Christoph
AU - Yaspo, Marie-Laure
AU - Korbel, Jan O
AU - Schlomm, Thorsten
AU - Weischenfeldt, Joachim
N1 - Copyright © 2018 Elsevier Inc. All rights reserved.
PY - 2018/12/10
Y1 - 2018/12/10
N2 - Identifying the earliest somatic changes in prostate cancer can give important insights into tumor evolution and aids in stratifying high- from low-risk disease. We integrated whole genome, transcriptome and methylome analysis of early-onset prostate cancers (diagnosis ≤55 years). Characterization across 292 prostate cancer genomes revealed age-related genomic alterations and a clock-like enzymatic-driven mutational process contributing to the earliest mutations in prostate cancer patients. Our integrative analysis identified four molecular subgroups, including a particularly aggressive subgroup with recurrent duplications associated with increased expression of ESRP1, which we validate in 12,000 tissue microarray tumors. Finally, we combined the patterns of molecular co-occurrence and risk-based subgroup information to deconvolve the molecular and clinical trajectories of prostate cancer from single patient samples.
AB - Identifying the earliest somatic changes in prostate cancer can give important insights into tumor evolution and aids in stratifying high- from low-risk disease. We integrated whole genome, transcriptome and methylome analysis of early-onset prostate cancers (diagnosis ≤55 years). Characterization across 292 prostate cancer genomes revealed age-related genomic alterations and a clock-like enzymatic-driven mutational process contributing to the earliest mutations in prostate cancer patients. Our integrative analysis identified four molecular subgroups, including a particularly aggressive subgroup with recurrent duplications associated with increased expression of ESRP1, which we validate in 12,000 tissue microarray tumors. Finally, we combined the patterns of molecular co-occurrence and risk-based subgroup information to deconvolve the molecular and clinical trajectories of prostate cancer from single patient samples.
KW - Journal Article
U2 - 10.1016/j.ccell.2018.10.016
DO - 10.1016/j.ccell.2018.10.016
M3 - SCORING: Journal article
C2 - 30537516
VL - 34
SP - 996-1011.e8
JO - CANCER CELL
JF - CANCER CELL
SN - 1535-6108
IS - 6
ER -